A Randomized Phase II Study of the Clinical and Metabolic Effects Of Conventional RT with Upfront ADT vs Escalated Dose Hypofractionated RT With Prompt ADT Salvage in High-Risk Prostate Cancer
The proposed study will examine the clinical and metabolic implications of using escalated dose hypofractionated RT with prompt ADT salvage in comparison to upfront ADT with conventional RT.
Patients with high risk prostate cancer will be randomized to receive either conventional therapy (conventional RT + upfront ADT) or the investigational therapy (hypofractionated RT + prompt ADT salvage). Patients will be evaluated for acute radiation treatment related toxicities at each visit throughout the treatment period as well as at 6 weeks following the end of treatment.
Patients will continue to be followed at the Cancer Centre in accordance with standard clinical practice as follows:
In addition, metabolic evaluations will be conducted at the University of Waterloo at the end of treatment and at 6 months following the 6 week post end of treatment visit.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society